Treatment induced or treatment-boosted ADA were detected in in 11% (27/257 patients) in TRANSCEND, 7% (6/84 patients) in TRANSCEND-CLL, 18% (18/100 patients) in TRANSCEND-FL, 18% (15/85 patients) in TRANSCEND-MCL, 1% (1/89 patients) in TRANSFORM, and 2% (1/49 patients) in PILOT (51). Here, ADA is linked to B-cell chronic lymphocytic leukemia.